Slingshot Biosciences, an Emeryville, CA-based biotechnology company building an on-demand synthetic cell platform for customizing cell and cell line mimics, raised $11m in Series A3 financing.
The round was co-led by Arch Venture Partners, with participation from Anterra Capital.
The company intends to use the funds to accelerate the commercialization of its technology for cell and gene therapies, and further develop its adoptive cell therapy and therapeutics platform.
Led by Jeffrey Kim, PhD, Founder, CEO, and President, Slingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics. The company leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets.
FinSMEs
06/02/2023